WVE

WVE

USD

Wave Life Sciences Ltd. Ordinary Shares

$8.010+0.000 (0.000%)

Precio en Tiempo Real

Healthcare
Biotecnología
Singapur

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$8.010

Máximo

$8.270

Mínimo

$7.950

Volumen

1.95M

Fundamentos de la Empresa

Capitalización de Mercado

1.3B

Industria

Biotecnología

País

Singapore

Estadísticas de Negociación

Volumen Promedio

2.52M

Bolsa

NGM

Moneda

USD

Rango de 52 Semanas

Mínimo $5.28Actual $8.010Máximo $16.74

Noticias Relacionadas

GlobeNewswire

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or

Ver más
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
GlobeNewswire

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will

Ver más
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
GlobeNewswire

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

This press release corrects and replaces the company's press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under "WVE-007 (GalNAc-siRNA)" – "Next steps."

Ver más
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
GlobeNewswire

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well

Ver más
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Analyst Upgrades

Clear Street Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $22

Clear Street analyst Bill Maughan initiates coverage on WAVE Life Sciences with a Buy rating and announces Price Target of $22.

Ver más
Clear Street Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $22

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.